Retatrutide vs Tirzepatide: Receptor Targets and Evidence

Short answer

They are different molecules, with different receptor profiles and different regulatory and evidence maturity. This page does not answer which is “better” and does not recommend switching treatment.

Mounjaro and Zepbound appear only to situate names: in the United States, tirzepatide is the active ingredient of FDA-approved products. The definition of retatrutide is in what retatrutide is. The triple profile is explained in how it works.

Receptor profile

Retatrutide is described in the discovery literature and in the NEJM Phase 2 trial as an agonist of the GIP, GLP-1, and glucagon receptors.^1,2

Tirzepatide is described in U.S. Zepbound prescribing information as an agonist of the GIP and GLP-1 receptors.³

Three targets versus two is a profile difference. It is not, by itself, a demonstration of a larger clinical effect. A reader who turns that difference into “retatrutide is the next version of tirzepatide” is reading marketing, not this page’s sources.

Development and regulatory status

Retatrutide remains an investigational compound and is not currently approved by the FDA. Lilly states that it has not been approved by any agency. A completed clinical phase or a positive result is not a regulatory authorization.⁵

The FDA approved Zepbound (tirzepatide) for chronic weight management on November 8, 2023. That approval is U.S.-specific and refers to a specific product, not to “tirzepatide” as an abstract idea and not to retatrutide.⁴

The FDA page on unapproved GLP-1 drugs discusses, in the United States, consumer-marketed retatrutide products. That source is not translated here into a claim about Mexican law.⁶

Evidence maturity

Tirzepatide, as the active ingredient of U.S.-approved products, has undergone regulatory review and has labeling. That maturity is not copied onto retatrutide.

Retatrutide has discovery and Phase 2 papers, a Phase 3 program in the registry or in topline announcement, and, in this page’s sources, no authorization. Detailed clinical status is in retatrutide clinical trials.

Is there a direct head-to-head trial?

In the sources reviewed for this page, we did not identify a published randomized trial that directly compares retatrutide and tirzepatide. That sentence is limited to this review’s source set, dated September 1, 2026. It is not a universal negative beyond that set.

A published head-to-head trial would, in principle, allow both molecules to be compared under the same protocol. Without that trial, any cross-trial percentage table invents a comparison the sources do not support. Retatrutide’s clinical status, including TRIUMPH, is in clinical trials, not in a ranking against Mounjaro.

Why percentages from separate trials cannot simply be compared

Separate trials can differ in population, duration, endpoints, estimands, protocols, and treatment conditions. Placing a percentage from a retatrutide trial next to a percentage from a tirzepatide trial and declaring a winner treats those studies as if they were head-to-head. They are not.

If another page cites TRIUMPH figures, those figures are attributed to Lilly and left in their trial. They are not aligned here with Zepbound figures or other protocols. Receptor count is not used as a shortcut either: “triple” does not mean “more effective than dual.”

This comparison is also not a treatment-access guide, not an approval prediction, and not an equivalence between a Peptra research material and an approved tirzepatide product. A Peptra certificate documents a Peptra lot; it does not place that lot inside a Lilly trial or an FDA-approved product.

The cluster index is the Retatrutide research hub.